Figure 5.

Effects of exendin-4 and DA-CH5 on insulin desensitization-related protein expression in 6-OHDA-treated SH-SY5Y cells.

Cells were treated with 350 µM of 6-OHDA with or without 100 nM of exendin-4 or DA-CH5 for 24 hours. (A) Bands of insulin desensitization-related proteins. β-Actin was used as the loading control. (B–D) Quantitative results of p-IRS-1^ser312 (B), p-Akt^ser473 (C), and p-CREB^ser129 (D) expression. All data are represented as the mean ± SD of quadruplicate independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, vs. control group (CON); †P < 0.05, ††P < 0.01, vs. 6-OHDA group; §P < 0.05, vs. 6-OHDA + exendin-4 group (one-way analysis of variance followed by Tukey’s multiple comparison test). 6-OHDA: 6-Hydroxydopamine; Akt: alpha serine/threonine-protein kinase; CREB: cAMP response element-binding protein; exendin-4 and DA-CH5: glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide dual receptor agonist; IRS-1: insulin receptor substrate-1; PD: Parkinson’s disease.